- Home
- PMEC vs OTLK Comparison
PMEC vs OTLK Comparison
Compare PMEC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | OTLK |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 29.2M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PMEC | OTLK |
|---|---|---|
| Price | $0.72 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 36.2K | ★ 4.9M |
| Earning Date | 07-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.16 |
| 52 Week High | $2.44 | $3.39 |
Technical Indicators
Market Signals| Indicator | PMEC | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 52.67 |
| Support Level | $0.62 | $0.17 |
| Resistance Level | $0.79 | $0.46 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 52.18 | 63.43 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.